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In vitro Antimicrobial Activity of the Aminoglycoside Arbekacin Tested Against
Oxacillin-Resistant Staphylococcus aureus Isolated in Brazilian Hospitals
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Helio S. Sader and The Arbekacin Study Group of Infectious Diseases, Universidade Federal de São
Paulo, SP, Brazil
Arbekacin is an aminoglycoside used in Japan for treating infections caused by gentamicin
and oxacillin-resistant S. aureus (ORSA). The objective of this study was to determine the in vitro
antimicrobial activity of arbekacin against 454 clinical isolates of ORSA. The isolates were
consecutively collected between January and July, 2000, from patients hospitalized in 8 Brazilian
medical centers. The antimicrobial susceptibility testing was performed by disk diffusion method
according to NCCLS recommendations. The vast majority of the isolates, 453 strains (99.8%),
were considered susceptible to arbekacin based on the criteria proposed by the Requirements for
Antibiotic Products of Japan. Only 1 isolate (0.2%) was classified as resistant. On the other
hand, high rates of resistance were demonstrated for other aminoglycosides, such as gentamicin
(97.6% resistance) and amikacin (97.0% resistance). Resistance rate was also high for
ciprofloxacin (98.0%). All isolates were considered susceptible to vancomycin. The excellent in
vitro antimicrobial activity of arbekacin demonstrated in this study indicates that this antimicrobial
agent may play an important role in the treatment of severe ORSA infections, especially those
that show poor clinical response with vancomycin monotherapy. Since the aminoglycosides should
not be used as monotherapy to treat Gram positive infections, further studies evaluating in vitro
and in vivo synergistic activity of arbekacin combinations are necessary to clarify the clinical
role of this aminoglycoside.
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Infections due to ORSA strains represent a
serious clinical and epidemiologic problem,
especially among seriously ill inpatients [1]. Most
strains of ORSA exhibit high-level resistance to most
commercially available antimicrobial agents.
Vancomycin has been the main antimicrobial agent
for treating infections caused by ORSA [1, 2].
However, S. aureus with intermediate resistance to
glycopeptides has been reported in Japan, USA,
France, and Hong Kong [3,4]. Although the level
of resistance is low, treatment with vancomycin failed
in most of the reported cases, raising concerns that
treatment of ORSA infections may become even
more problematic in the future [3, 4].
The vast majority of  S. aureus strains with reduced
susceptibilities to vancomycin, described until now have
initially been ORSA strains that developed decreased
susceptibility to vancomycin after prolonged exposure
to this compound [3, 4]. The prolonged use of
vancomycin will likely lead to additional resistance by
Gram positive organisms. Therefore, the potential for
continuing emergence of S. aureus strains with
intermediate resistance to vancomycin increases the
need for new therapeutic options [5].
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Aminoglycosides have been used to treat bacterial
infections for a long time [1]. The critical resistance
mechanisms to aminoglycoside antibiotics in bacteria
of clinical importance are the enzymatic N-acetylation,
O-nucleotidylation and O-phosphorylation, that
generally results in the inactivation of these compounds
[6]. The genes for these aminoglycoside-modifying
enzymes are located mainly on plasmids [7]. Organisms
expressing resistance due to decreased aminoglycoside
permeability have also been reported, and resistance
due to altered target (ribosome modifications) is rare
among clinical isolates [6]. Studies of the resistance
mechanism and chemical modifications of
aminoglycoside antibiotics led to the synthesis of
arbekacin in 1973, from the 1-N-acylation of dibekacin
with (S)-4-amino-2-hydroxybutyric acid [6]. Arbekacin
is an aminoglycoside with broad spectrum of
antimicrobial activity, which includes bacteria resistant
to kanamycin, gentamicin and tobramycin [2, 6].
Arbekacin is active in vitro against both Gram negative
and Gram positive aerobic bacteria, and it is refractory
to hydrolysis by most aminoglycoside modifying
enzymes produced by aerobic bacteria [6].
Arbekacin was introduced in Japan in the late 1990s
as a useful chemotherapeutic agent for the treatment of
infections caused by ORSA [8]. Arbekacin acts by
binding to both 50S and 30S ribosomal sub-units. Thus,
it inhibits protein synthesis at bacterial ribosomes and causes
codon misreading [6, 9]. The high stability of arbekacin in
the presence of inactivating enzymes produced by ORSA,
such as 2”-aminoglycoside-phosphotransferase, 4”-
aminoglycoside-adenylyltransferase and 3”-aminoglycoside-
phosphotransferase causes gentamicin-resistant ORSA
strains to be susceptible to this antimicrobial agent [6, 10].
The objective of this study is to determine the in vitro
antimicrobial activity profile of arbekacin against clinical
ORSA isolates collected in Brazilian medical centers.
Materials and Methods
Bacterial samples
Four hundred fifty four clinical ORSA isolates were
included in the study. The isolates were consecutively
collected between January to July, 2000, in 8 Brazilian
medical centers. The following centers were included
in the study: Laboratório Especial de Microbiologia
Clínica - Hospital São Paulo (LEMC), São Paulo (126
strains); Laboratório de Investigações Médicas da
Universidade de São Paulo (LIM-54), São Paulo (60
strains); Hospital de Base de Brasília (HBB), Distrito
Federal (85 strains); Hospital de Clínicas de Porto
Alegre (HCPA), Rio Grande do Sul (50 strains);
Laboratório Médico Santa Luzia (LMSL),
Florianópolis, Santa Catarina (45 strains); Messejana
Hospital (MH), Fortaleza, Ceará (34 strains); Real
Hospital Beneficiência Portuguêsa (RHBP), Recife,
Pernambuco (30 strains); and Hospital Universitário
da Universidade Federal do Rio de Janeiro (HU-
UFRJ), Rio de Janeiro (24 strains). Two other medical
centers (Emílio Ribas Hospital, São Paulo, and
Laboratório Médico Jorge Saliba, Belo Horizonte,
Minas Gerais) participated in the study; however, their
results were excluded from the analyses because the
strains were not saved for re-testing and/or
confirmation of the initial results.
Antimicrobial susceptibility tests
The samples were evaluated using the disk diffusion
method according to standards of the National
Committee for Clinical Laboratory Standards
(NCCLS) [11]. The susceptibility tests were performed
by each participanting center. The antimicrobial agents
evaluated were as follows: arbekacin (30 mg disk),
vancomycin (30 mg disk), oxacillin (1 mg disk),
amikacin (30 mg disk), ciprofloxacin (5 mg disk), and
gentamicin (10 mg disk). All isolates with reduced
susceptibility to arbekacin (inhibition zone ≤20 mm)
and/or vancomycin were sent to the coordinator center
for retest. The isolates were categorized as susceptible,
intermediate, and resistant according to the standards
established by the NCCLS [11]. The interpretation
criteria used for arbekacin were based on the
Requirements for Antibiotic Products of Japan, that is
cited in its package insert [12]. This document classifies
the isolates as follows: susceptible when inhibition zone
diameter is ≥21 mm, moderately susceptible when
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Figure 1. Distribution of arbekacin zone diameters for 454 oxacillin-resistant Staphylococcus aureus (ORSA)
isolates
Table 1. Antimicrobial susceptibility pattern of ORSA strains from Brazilian hospitals
Figure 2. ORSA isolate showing in vitro susceptibility only to arbekacin and vancomycin
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Arbekacin 0.2 0.0 99.8
Gentamicin 97.6 1.3 1.1
Amikacin 97.0 0.4 2.6
Ciprofloxacin 98.0 0.2 1.8
Oxacillin 100.0 0.0 0.0
Vancomycin 0.0 0.0 100.0
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Table 2. Antimicrobial susceptibility pattern of ORSA strains according to the participating centers
inhibition zone diameter is 16 mm-20 mm, moderately
resistant when inhibition zone diameter is 10 mm-15 mm,
and totally resistant when zone diameter is ≤9 mm. S
aureus ATCC 25923 was tested along with each series
of susceptibility tests as quality control [13].
Results
The antimicrobial susceptibility patterns of the isolates
for arbekacin and 5 other antimicrobial agents are shown
in Table 1. Based on the Requirements for Antibiotic
Products of Japan [12] only 1 isolate (0.2%) was
considered resistant to arbekacin. Twenty-seven isolates
(6.0%) had arbekacin inhibition zones between 18 mm
and 20 mm of diameter (Figure 1). These isolates are
considered moderately susceptible based on the criteria
used in Japan. However, the analysis of the distribution
of inhibition diameter zones (Figure 1) indicates that these
isolates are included in the normal population. Thus, these
strains were considered susceptible to arbekacin. Also,
the collection showed very high rates of resistance to
other antimicrobial agents evaluated: 97.6% gentamicin
resistance, 97.0% amikacin resistance, and 98.0%
ciprofloxacin resistance. One of these ORSA isolates
showing susceptibility only to arbekacin and vancomycin
is shown in Figure 2.
The only arbekacin-resistant strain detected in the
study was isolated in a patient hospitalized at the
Hospital São Paulo. The moderately susceptible strains
were isolated in the Laboratório Especial de
Microbiologia Clínica (10 isolates), Laboratório de
Investigações Médicas da Universidade de São Paulo
(11 isolates); Hospital de Clínicas de Porto Alegre (3
isolates); Real Hospital Beneficiência Portuguêsa (2
isolates), Hospital Universitário da Universidade Federal
do Rio de Janeiro (1 isolate). Three participant centers
did not detect any isolate moderately susceptible to
arbekacin: Hospital de Base de Brasília, Laboratório
Médico Santa Luzia, and Messejana Hospital.
Discussion
Staphylococcus aureus, especially oxacillin-
resistant S. aureus (ORSA) has become a major cause
of nosocomial infections [14]. In Brazil, the vast majority
of ORSA isolates show cross-resistance to other
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Center (n) % Susceptible Strains
Arbekacin Gentamicin Ciprofloxacin Vancomycin
LEMC (126) 99.2 2.4 2.4 100.0
LIM-54 (60) 100.0 0.0 0.0 100.0
HBB (85) 100.0 0.0 0.0 100.0
HCPA (50) 100.0 2.0 2.0 100.0
LMSL (45) 100.0 0.0 0.0 100.0
MH (34) 100.0 0.0 8.8 100.0
RHBP (30) 100.0 0.0 0.0 100.0
HU-UFRJ (24) 100.0 4.2 4.2 100.0
Total (454) 99.8 1.1 1.8 100.0
LEMC: Laboratório Especial de Microbiologia Clínica – Hospital São Paulo; LIM-54: Laboratório de
Investigações Médicas da Universidade de São Paulo; HBB: Hospital de Base de Brasília; HCPA: Hospital de
Clínicas de Porto Alegre; LMSL: Laboratório Médico Santa Luzia; MH: Messejana Hospital; RHBP: Real
Hospital Beneficiência Portuguesa; HU-UFRJ: Hospital Universitário da Universidade Federal do Rio de
Janeiro.
134 BJID 2001; 5 (June)
www.infecto.org.br/bjid.htm
antimicrobial agents, including other β-lactams,
macrolides, clindamycin, ciprofloxacin, trimethoprim/
sulfamethozaxole, and aminoglycosides, leaving very
few therapeutic options to treat infections caused by
this microorganism [15]. The high prevalence of cross-
resistance to other antimicrobial agents is related to
the dissemination of transposons with insertion
sequences in the 50-kb mec region gene [16,17]. For
example, the transposon Tn554 contains the ermA
gene, which encodes inducible erythromycin resistance,
and the IS431, an insertion sequence associated with
resistance determinants is extremely common. The
ability of IS431 elements through homologous
recombination to trap and cluster resistance
determinants with similar IS elements explains the
multiple drug resistance phenotype that is characteristic
of ORSA strains [16, 17].
This high level of resistance among ORSA strains is
of great concern [3, 4]. Therefore, there is an urgent
need for alternative therapeutic options for the treatment
of infections caused by this microorganism [4].
Arbekacin, an aminoglycoside synthesized in Japan,
has been evaluated in several comparative studies to
define its clinical efficacy and its synergistic effect with
other antimicrobial agents, such as vancomycin and
ampicillin-sulbactam [2,8,18-20]. Arbekacin-resistant
mutants can be selected at a frequency of 10-4 to 10-5
among gentamicin-resistant ORSA strains by exposure
to subinhibitory concentrations of arbekacin [21, 22].
The arbekacin-resistant mutants may express a
bifunctional enzyme, AAC(6’)/APH(2”), that is able
to modify arbekacin [21, 22]. However, further studies
are necessary to evaluate the resistance mechanism
present in the strain detected in the present study.
Since arkekacin is commercially available in very
few countries, its breakpoints for disk diffusion have
not been widely evaluated. The analysis of population
distribution according to arbekacin inhibition diameter
zone clearly shows that isolates classified as “moderately
susceptible” (inhibition zones of 16 mm to 20 mm) by
the Requirements for Antibiotic Products of Japan are
within the normal population and should be considered
susceptible (Figure 1). Further studies evaluating the
arbekacin minimum inhibitory concentration (MIC) of
these strains are necessary to clarify the in vitro activity
of arbekacin against these strains. On the other hand,
the isolate with an inhibition zone of 6 mm is clearly out
of the normal population and has probably acquired a
mechanism of resistance to this new aminoglycoside.
The excellent in vitro activity showed in this first
Brazilian benchmark study, coupled with the
therapeutic efficacy demonstrated in treating infections
caused by ORSA and GISA isolates in Japan,
indicates that arbekacin may be a reasonable
alternative for the treatment of ORSA and GISA
infections in association with other anti-staphylococcal
drugs [4, 18]. Further studies evaluating its
antimicrobial potency and synergistic effect with other
compounds will contribute to clarify the clinical role
of this antimicrobial agent.
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